Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia

Autor:	Gail J. Roboz, Catherine B. Lagassa, Ellen K. Ritchie, Cindy Ippoliti, Sarah D. Rohan, Karen Carlson, Eric J. Feldman, Paul J. Christos, Joseph M. Scandura
Rok vydání:	2013
Předmět:	Male Oncology Antimetabolites Antineoplastic Cancer Research medicine.medical_specialty Myeloid Azacitidine Decitabine Article Cohort Studies Refractory Recurrence hemic and lymphatic diseases Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Aged Aged 80 and over business.industry Remission Induction Myeloid leukemia Hematology Middle Aged medicine.disease Surgery Leukemia Myeloid Acute Regimen Leukemia Treatment Outcome medicine.anatomical_structure Hypomethylating agent Female business medicine.drug
Zdroj:	Leukemia & Lymphoma. 54:2003-2007
ISSN:	1029-2403 1042-8194
Popis:	Treatment options for older patients with acute myeloid leukemia (AML) and for patients with relapsed/refractory AML are limited, and outcomes are poor. Decitabine, a hypomethylating agent, is active in patients with myelodysplastic syndrome (MDS) and AML, but its optimal dose and schedule are unknown. We report the efficacy and safety of repeated 10-day cycles of decitabine 20 mg/m(2) administered intravenously over 1 h in 52 newly diagnosed and 102 relapsed/refractory patients. Repeated 10-day cycles of decitabine produced a complete response (CR) in 40% of newly diagnosed older patients with AML, many of whom had adverse prognostic features. The median overall survival (OS) was 318 days but there was prolonged survival in responders of 481 days. Relapsed/refractory patients had a CR rate of 15.7% with a median OS of 177 days. Extramedullary toxicity was mild and the regimen was well tolerated for ongoing post-remission, outpatient maintenance cycles. Responses were durable for over 1 year.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d63d3b12e62bee141cc4707dbe296c33 https://doi.org/10.3109/10428194.2012.762093 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.